Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action
Cliff Battram, Steven J. Charlton, Bernard Cuenoud, Mark R. Dowling, Robin A. Fairhurst, David Farr, John R. Fozard, Juliet R. Leighton-Davies, Christine A. Lewis, Lorraine McEvoy, Robert J. Turner and Alexandre Trifilieff
Journal of Pharmacology and Experimental Therapeutics May 2006, 317 (2) 762-770; DOI: https://doi.org/10.1124/jpet.105.098251
Cliff Battram
Steven J. Charlton
Bernard Cuenoud
Mark R. Dowling
Robin A. Fairhurst
David Farr
John R. Fozard
Juliet R. Leighton-Davies
Christine A. Lewis
Lorraine McEvoy
Robert J. Turner

Log in using your username and password
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Journal of Pharmacology and Experimental Therapeutics
Vol. 372, Issue 1
1 Jan 2020
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action
Cliff Battram, Steven J. Charlton, Bernard Cuenoud, Mark R. Dowling, Robin A. Fairhurst, David Farr, John R. Fozard, Juliet R. Leighton-Davies, Christine A. Lewis, Lorraine McEvoy, Robert J. Turner and Alexandre Trifilieff
Journal of Pharmacology and Experimental Therapeutics May 1, 2006, 317 (2) 762-770; DOI: https://doi.org/10.1124/jpet.105.098251
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action
Cliff Battram, Steven J. Charlton, Bernard Cuenoud, Mark R. Dowling, Robin A. Fairhurst, David Farr, John R. Fozard, Juliet R. Leighton-Davies, Christine A. Lewis, Lorraine McEvoy, Robert J. Turner and Alexandre Trifilieff
Journal of Pharmacology and Experimental Therapeutics May 1, 2006, 317 (2) 762-770; DOI: https://doi.org/10.1124/jpet.105.098251